SCHEMBL8293180

SCHEMBL8293180

CCOC(=O)CN1CCC(Nc2nc3ccc(CO)cc3n2Cc2nc(C)ccc2O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 8/20 0.40
KCNH2 Q12809 7/20 0.40
NR4A2 P43354 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HRH1 P35367 2/20 0.38
HRH4 Q9H3N8 2/20 0.38
EED O75530 2/20 0.38
MEN1 O00255 1/20 0.38
MLNR O43193 1/20 0.38
CACNA1F O60840 1/20 0.38
USP2 O75604 1/20 0.38
ABCB11 O95342 1/20 0.38
EGFR P00533 1/20 0.38
HLA-A P04439 1/20 0.38
ERBB2 P04626 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
LCK P06239 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8293629 0.92 KCNH2 (0.42) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8292651 0.92 KCNH2 (0.41) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL12852036 0.90 KCNH2 (0.42) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8294931 0.89 SSTR5 (0.37) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8294770 0.88 PDE5A (0.37) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8294932 0.87 SSTR5 (0.37) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8294206 0.85 KCNH2 (0.43) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8285490 0.84 SSTR5 (0.58) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8284433 0.84 KCNH2 (0.46) SSTR5KCNH2NR4A2LMNAGAA
SCHEMBL8294759 0.82 KCNH2 (0.41) SSTR5KCNH2NR4A2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed
WO-2005058874-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 SSTR5 2982/4885KCNH2 368/4885NR4A2 331/4885
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 SSTR5 3585/4885KCNH2 419/4885NR4A2 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.